Sepsis Syndrome Clinical Trial
Official title:
Metabolism of Branched-chain Amino Acids in Monocyte and Macrophage During Sepsis
Verified date | February 2019 |
Source | West China Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The current project was designed to examine the metabolic level of branched-chain amino acids in plasm and monocyte/macrophage, and its role in immune dysfunction during sepsis.
Status | Not yet recruiting |
Enrollment | 90 |
Est. completion date | February 28, 2022 |
Est. primary completion date | December 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - patients diagnosed with sepsis, with or without type 2 diabetes - healthy volunteers Exclusion Criteria: - patients with immunodeficient diseases - patients who accept glucocorticoid or immunosuppressant - patients with an age younger than 18 years - patients who cannot provide the informed consent |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
West China Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intracellular levels of branched-chain amino acids in monocytes | BCAAs Assay Kit will be used to measure the intracellular levels of BCAAs in monocytes. | up to 14 day after diagnose of sepsis | |
Secondary | Plasma levels of branched-chain amino acids | BCAAs Assay Kit will be used to measure the plasma levels of BCAAs. | 1,3,5,7,10,14 day after diagnose of sepsis | |
Secondary | The expression of branched-chain amino acid aminotransferase in monocytes | The expression of branched-chain amino acid aminotransferase in monocytes will be determined by qPCR and western blot. | 1,3,5,7,10,14 day after diagnose of sepsis | |
Secondary | The expression of branched-chain a-ketoacid dehydrogenase in monocytes | The expression of branched-chain a-ketoacid dehydrogenase in monocytes will be determined by qPCR and western blot. | 1,3,5,7,10,14 day after diagnose of sepsis | |
Secondary | The expression of PP2Cm in monocytes | The expression of mitochondrial-targeted phosphatase, PP2Cm in monocytes will be determined by qPCR and western blot. | 1,3,5,7,10,14 day after diagnose of sepsis | |
Secondary | The plasma level of IL-1ß | The plasma level of IL-1ß will be determined by ELISA kit. | 1,3,5,7,10,14 day after diagnose of sepsis. | |
Secondary | The plasma level of TNF-a | The plasma level of TNF-a will be determined by ELISA kit. | 1,3,5,7,10,14 day after diagnose of sepsis. | |
Secondary | The plasma level of IL-10 | The level of IL-10 will be determined by ELISA kit. | 1,3,5,7,10,14 day after diagnose of sepsis. | |
Secondary | The plasma level of chemokine MIP-1a. | The plasma level of chemokine MIP-1a will be determined by ELISA kit. | 1,3,5,7,10,14 day after diagnose of sepsis. | |
Secondary | The plasma level of chemokine MIP-1ß. | The plasma level of chemokine MIP-1ß will be determined by ELISA kit. | 1,3,5,7,10,14 day after diagnose of sepsis. | |
Secondary | The phagocytic index of monocytes. | The phagocytic index of monocytes will be determined by a E.coli Phagocytosis Assay Kit. | 1,3,5,7,10,14 day after diagnose of sepsis. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04560842 -
The Efficacy of High-flow Nasal Cannula Oxygen Therapy in Sepsis Patients
|
N/A | |
Completed |
NCT04475081 -
Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis
|
Phase 3 | |
Completed |
NCT03314831 -
The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
|
||
Completed |
NCT03371680 -
Kinetics of Surfactant Proteins, Phosphatidylcholine and Body Water in Intensive Care Unit (ICU)
|
N/A | |
Completed |
NCT00046072 -
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
|
Phase 2 | |
Enrolling by invitation |
NCT05602584 -
Effect of Immunophenotype on Prognosis of Sepsis
|
||
Completed |
NCT06338111 -
Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department
|
||
Completed |
NCT04292431 -
Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)
|
||
Recruiting |
NCT03472170 -
Clinical Trial for Valuation of the Effectiveness of Lactoferrine in the Prevention of Sepsis in New Premature Born. Bimonitorization of the Antinflammatory Mechanisms, Antioxidants and the Intestinal Microbiote.
|
N/A | |
Not yet recruiting |
NCT05382078 -
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
|
||
Recruiting |
NCT03956043 -
Diagnostic Accuracy in Sepsis
|
||
Recruiting |
NCT05977153 -
CT for Personalized Mechanical Ventilation
|
N/A | |
Completed |
NCT00448968 -
The Utility of Ischemia Modified Albumin (IMA) in Sepsis
|
N/A | |
Completed |
NCT05246969 -
Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage
|
||
Not yet recruiting |
NCT06446947 -
Identification of Markers of Poor Clinical Prognosis in Sepsis by Epigenetic Analysis
|
||
Recruiting |
NCT05261607 -
Analysis of the Evolution of Mortality in an Intensive Care Unit
|
||
Recruiting |
NCT04203979 -
Sepsis: From Syndrome to Personalized Care
|
||
Recruiting |
NCT03990467 -
Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU
|
N/A | |
Recruiting |
NCT05338359 -
Metrology to Enable Rapid and Accurate Clinical Measurements in Acute Management of Sepsis
|
||
Completed |
NCT02562261 -
Platelet REactivity in Sepsis Syndrome (PRESS)
|